Anzeige
Mehr »
Dienstag, 03.06.2025 - Börsentäglich über 12.000 News
Gestern Kursverdopplung durch Uran-Hoffnung - zündet jetzt der nächste Vervielfacher?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A4114D | ISIN: US3622AW4030 | Ticker-Symbol:
NASDAQ
03.06.25 | 17:18
1,410 US-Dollar
+10,16 % +0,130
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GRI BIO INC Chart 1 Jahr
5-Tage-Chart
GRI BIO INC 5-Tage-Chart

Aktuelle News zur GRI BIO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
23.05.GRI Bio erweitert Kapazität für At-the-Market-Angebot2
23.05.GRI Bio, Inc. - 8-K, Current Report1
22.05.GRI Bio reports progress in pulmonary fibrosis treatment1
22.05.GRI Bio verzeichnet Fortschritte bei Behandlung von Lungenfibrose2
GRI BIO Aktie jetzt für 0€ handeln
22.05.GRI Bio, Inc.: GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results2
21.05.GRI Bio, Inc.: GRI Bio to Participate in the Virtual Investor Closing Bell Series1
16.05.GRI Bio, Inc.: GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase5
15.05.GRI Bio reports Q1 results2
15.05.GRI Bio reports positive early trial data for IPF treatment3
15.05.GRI Bio, Inc. - 10-Q, Quarterly Report-
15.05.GRI Bio, Inc. - 8-K, Current Report1
15.05.GRI Bio, Inc.: GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025132Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis ("IPF") Continued momentum with completed...
► Artikel lesen
08.05.GRI Bio reports positive interim biomarker data in IPF study1
08.05.GRI Bio meldet positive Zwischenergebnisse bei Biomarkern in IPF-Studie-
08.05.GRI Bio, Inc.: GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF")108The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed Continued momentum with completed patient...
► Artikel lesen
07.05.GRI Bio, Inc.: GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF") 145Enrollment completed for the 6-week interim analysis with 24 of the 36 planned patients now enrolled Company on track to report interim biomarker data from the first 12 patients imminently Completion...
► Artikel lesen
05.05.GRI Bio, Inc. - 8-K, Current Report1
14.04.H.C. Wainwright maintains Buy on GRI Bio stock, $10 target2
02.04.GRI Bio, Inc.: GRI Bio Announces Closing of $5.0 Million Public Offering1
02.04.GRI Bio, Inc. - 8-K, Current Report2
Seite:  Weiter >>
52 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1